• Publications
  • Influence
The use of melatonin in Alzheimer's disease.
TLDR
Melatonin treatment seems to constitute a selection therapy to ameliorate sundowning and to slow evolution of cognitive impairment in AD patients, an effect seen regardless of the concomitant medication employed to treat cognitive or behavioral signs of AD. Expand
Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer’s disease
TLDR
Rare coding variants in TREM2, PLCG2, and ABI3 also modulate susceptibility to AD in populations from Argentina, and they may have a European heritage. Expand
Identification of PSEN2 mutation p.N141I in Argentine pedigrees with early-onset familial Alzheimer's disease
TLDR
This work investigates the presence of PSEN2 mutation p.N141I in Argentina and characterize the clinical phenotypes in 2 Argentine pedigrees (AR2 and AR3) with clinical symptoms of EOFAD and increases the total number of described families carrying this mutation. Expand
Melatonin Efficacy to Treat Circadian Alterations of Sleep in Alzheimer’s Disease
TLDR
Melatonin prevented the chronobiological consequences of injecting β amyloid peptide 25–35 in the SCN of hamsters and cognitive decay in transgenic mice overexpressing β-amyloid, and could be beneficial in AD by augmenting the restorative phase of sleep. Expand
RARE VARIANTS IN PLCG2, ABI3, AND TREM2 GENES ARE ASSOCIATED WITH ALZHEIMER’S DISEASE IN AN ARGENTINIAN SAMPLE: IS IT A EUROPEAN HERITAGE?
TLDR
This research presents a novel and scalable approach called “cell reprograming” that allows for real-time annotation of the FISH signal of Alzheimer’s Disease through a probabilistic approach. Expand